rap-219
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 9, 2024 (NCT06377930)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
CACNG8 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07219407 | Phase 2 | Nov 3, 2025 | Rapport Therapeutics Inc., Yale University |
| NCT07046494 | Phase 2 | Jul 25, 2025 | Rapport Therapeutics Inc. |
| NCT06377930 | Phase 2 | Oct 9, 2024 | Rapport Therapeutics Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rapport Therapeutics Inc. | For profit | 3 | 3 | 1 | 2024 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1